AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20599140 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 0
Study 17873679 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 43
Study 17873679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15901634 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide 20 mg daily (n=30)
Number of subjects: 45
Study 15901634 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=15)
Number of subjects: 45
Study 11842297 — intervention group
Group type: COMPARATOR
Intervention: SIT-birch + placebo
Number of subjects: 221
Study 11842297 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT-birch + anti-IgE
Number of subjects: 221
Study 11842297 — intervention group
Group type: COMPARATOR
Intervention: SIT-grass + placebo
Number of subjects: 221
Study 11842297 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT-grass + anti-IgE
Number of subjects: 221
Study 9473540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/8-2 mg
Number of subjects: 48
Study 9473540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/32 mg or more
Number of subjects: 48
Study 9473540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/4 mg or less
Number of subjects: 48
Study 9473540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) 1/8-1/4 mg
Number of subjects: 48
Study 7722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes
Number of subjects: 339
Study 7722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with insulin
Number of subjects: 339
Study 7722961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study 2500138 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (n = 43)
Number of subjects: 138
Study 2500138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (n = 46)
Number of subjects: 138
Study 2500138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 138
Study 29287817 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Rod (GR)
Number of subjects: 52
Study 29287817 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically Controlled Growing Rod (MCGR)
Number of subjects: 52
Study 29287817 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 29287817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum (across all groups)
Number of subjects: 52
Study 29287817 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron (across all groups)
Number of subjects: 52
Study 27940687 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Fio2 of 0.3 (Lowox group)
Number of subjects: 253
Study 27940687 — intervention group
Group type: COMPARATOR
Intervention: Initial Fio2 of 0.6 to 0.65 (Hiox group)
Number of subjects: 253
Study 25238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (leuprolide acetate 1 mg s.c. injection 3 days after ET)
Number of subjects: 300
Study 25238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (two sequential doses of leuprolide acetate 1 mg s.c. injections 3 and 6 days after ET)
Number of subjects: 300
Study 25238659 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine luteal phase support only)
Number of subjects: 300
Study 25238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and B (leuprolide acetate)
Number of subjects: 300
Study 25238659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 25238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 300
Study 21813073 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment (2 to 6 mg/d) for 2 weeks
Number of subjects: 145
Study 21813073 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine treatment (10 to 20 mg/d) for 10 weeks (for nonresponders)
Number of subjects: 145
Study 21122046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment for 49 weeks
Number of subjects: 63
Study 21122046 — intervention group
Group type: COMPARATOR
Intervention: Hot wax treatment for 49 weeks
Number of subjects: 63
Study 19034126 — intervention group
Group type: EXPERIMENTAL
Intervention: unpreserved 0.4% hyaluronic acid eye drops 150 mOsm/L
Number of subjects: 28
Study 19034126 — intervention group
Group type: COMPARATOR
Intervention: unpreserved 0.4% hyaluronic acid eye drops 300 mOsm/L
Number of subjects: 28
Study 16025230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ACE-inhibitor treatment (< 9 hours after MI)
Number of subjects: 845
Study 16025230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study 14728070 — intervention group
Group type: EXPERIMENTAL
Intervention: trimetazidine MR 35 mg
Number of subjects: 223
Study 14728070 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 223
Study 11748790 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d
Number of subjects: 120
Study 11748790 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 120
Study 11748790 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 120
Study 11748790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9420366 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness intervention
Number of subjects: 0
Study 9420366 — intervention group
Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 0
Study 7971411 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected-partner support
Number of subjects: 175
Study 7971411 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-partner support
Number of subjects: 175
Study 7971411 — intervention group
Group type: COMPARATOR
Intervention: No support
Number of subjects: 175
Study 3121795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 5
Study 3121795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2647933 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oral cyclosporine dose for 7 to 10 days
Number of subjects: 40
Study 2647933 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 40
Study 31132967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 502
Study 31132967 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 502
Study 29157293 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/day for 48 hours before surgery, increased to 10 mg/day for the first 24 hours after surgery, continued for 3 months)
Number of subjects: 172
Study 29157293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 172
Study 25547037 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention (psychoeducation and interoceptive exposure)
Number of subjects: 97
Study 25547037 — intervention group
Group type: COMPARATOR
Intervention: Health information control condition
Number of subjects: 97
Study 23955138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (CTCX group)
Number of subjects: 40
Study 23955138 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (CT group)
Number of subjects: 40
Study 23955138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20869704 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 523
Study 20869704 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 523
Study 19137265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day) for 3 months
Number of subjects: 30
Study 17127704 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a
Number of subjects: 518
Study 17127704 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of peginterferon alpha‐2a and lamivudine
Number of subjects: 518
Study 17127704 — intervention group
Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 518
Study 15185991 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training of dysphagia with oral care (once a week for 3 years)
Number of subjects: 21
Study 15185991 — intervention group
Group type: COMPARATOR
Intervention: Oral care (non-training group)
Number of subjects: 21
Study 15185991 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training of dysphagia with oral care
Number of subjects: 21
Study 11520728 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen (HeO(2))
Number of subjects: 18
Study 9778327 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke treadmill score (DTS)
Number of subjects: 0
Study 7930275 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 159
Study 7930275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 7930275 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus formation presence
Number of subjects: 159
Study 7930275 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus formation absence
Number of subjects: 159
Study 7930275 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of lesion
Number of subjects: 159
Study 3060429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 102
Study 3060429 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 102
Study 3060429 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Prazosin and Hydrochlorothiazide
Number of subjects: 102
Study 3060429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 102
Study 3060429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 102
Study 31688648 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (90%-95% of HRpeak)
Number of subjects: 215
Study 31688648 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate continuous training (60%-70% of HRpeak)
Number of subjects: 215
Study 31688648 — intervention group
Group type: COMPARATOR
Intervention: Recommendation of regular exercise on their own
Number of subjects: 215
Study 31112386 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-Formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation as needed)
Number of subjects: 668
Study 31112386 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (100 μg, two inhalations as needed)
Number of subjects: 668
Study 31112386 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (200 μg, one inhalation twice daily) plus as-needed albuterol
Number of subjects: 668
Study 28859664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 75
Study 28859664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 75
Study 28859664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of aerobic exercise and cognitive training
Number of subjects: 75
Study 28859664 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 25463413 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 25463413 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise training
Number of subjects: 2331
Study 25463413 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2331
Study 23458695 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 435
Study 22019960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (4%)
Number of subjects: 14
Study 22019960 — intervention group
Group type: COMPARATOR
Intervention: Placebo iontophoresis (normal saline)
Number of subjects: 14
Study 18093246 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 54
Study 18093246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plans submitted to the QA team of the START trial
Number of subjects: 1400
Study 16940374 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge angle used in radiotherapy plans
Number of subjects: 1400
Study 14870468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 patients)
Number of subjects: 90
Study 14870468 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients, no oxytocin)
Number of subjects: 90
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fuchsin
Number of subjects: 10
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizarin complexone
Number of subjects: 10
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcein
Number of subjects: 10
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcein blue
Number of subjects: 10
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline
Number of subjects: 10
Study 10815835 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylenol orange
Number of subjects: 10
Study 8978226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programmes comprising psychological therapy, counselling, relaxation training, and stress management training over seven weekly group outpatient sessions for patients and spouses.
Number of subjects: 2328
Study 8978226 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 2328
Study 1538611 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analyses included in RCTs
Number of subjects: 51
Study 1538611 — intervention group
Group type: COMPARATOR
Intervention: Later dates of publication
Number of subjects: 51
Study 1538611 — intervention group
Group type: COMPARATOR
Intervention: Presence of a statement of study perspective
Number of subjects: 51
Study 1538611 — intervention group
Group type: COMPARATOR
Intervention: Economic completeness and quality of research scores
Number of subjects: 51
Study 1538611 — intervention group
Group type: COMPARATOR
Intervention: Deficiencies in economic analyses
Number of subjects: 51
Study 6422914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer alpha-interferon (100 X 10(6) IU/mL)
Number of subjects: 0
Study 6422914 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine
Number of subjects: 0
Study 31439102 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent communication intervention plus in-vehicle event recorder feedback
Number of subjects: 0
Study 31439102 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle event recorder feedback only
Number of subjects: 0
Study 31439102 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 29451185 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stoma closure
Number of subjects: 100
Study 27692733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1861
Study 27692733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1861
Study 27692733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1861
Study 27692733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg
Number of subjects: 1861
Study 27692733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1861
Study 24731015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and review of airway clearance therapy (ACT) for 8 weeks
Number of subjects: 85
Study 24731015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 22738022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) active
Number of subjects: 8
Study 22738022 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS) off
Number of subjects: 8
Study 20644014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene score based on 2 PLTP single nucleotide polymorphisms
Number of subjects: 4658
Study 18679598 — intervention group
Group type: EXPERIMENTAL
Intervention: Neiguan (P6) electroacupoint stimulation
Number of subjects: 96
Study 18679598 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (placement of electrodes without electroacupoint stimulation)
Number of subjects: 96
Study 15960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention: one-time e-mail reminder highlighting six HF-specific clinical recommendations
Number of subjects: 354
Study 15960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented intervention: initial e-mail reminder supplemented by provider prompts, patient education material, and clinical nurse specialist outreach
Number of subjects: 354
Study 15960694 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 354
Study 12091679 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mL of contrast material at 2.5 mL/sec
Number of subjects: 70
Study 12091679 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of contrast material at 2.0 mL/sec
Number of subjects: 70
Study 12091679 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL of contrast material at 1.5 mL/sec
Number of subjects: 70
Study 12091679 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mL of contrast material at 1.0 mL/sec
Number of subjects: 70
Study 12091679 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine examinations with 40 seconds and 45 seconds start delays
Number of subjects: 70
Study 10069785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) at 60% of peak VO2, initially 3 times a week for 8 weeks, then twice a week for 1 year
Number of subjects: 99
Study 10069785 — intervention group
Group type: COMPARATOR
Intervention: No Exercise (Control group)
Number of subjects: 99
Study 7560641 — intervention group
Group type: EXPERIMENTAL
Intervention: Neocate formula for 2 months followed by a 7-day double-blind placebo-controlled challenge with the previously best tolerated formula
Number of subjects: 18
Study 7560641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 18
Study 2155531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon alfa-2b
Number of subjects: 42
Study 2155531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 387497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone alcoholic solution
Number of subjects: 55
Study 387497 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-17-alpha-butyrate
Number of subjects: 55
Study 31028547 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D white-light imaging
Number of subjects: 20
Study 31028547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3D and NBI
Number of subjects: 20
Study 31028547 — intervention group
Group type: COMPARATOR
Intervention: NBI
Number of subjects: 20
Study 31028547 — intervention group
Group type: COMPARATOR
Intervention: NIR-ICG
Number of subjects: 20
Study 31028547 — intervention group
Group type: COMPARATOR
Intervention: 2D white-light imaging
Number of subjects: 20
Study 31443072 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable outcome after aSAH treatment
Number of subjects: 5972
Study 31443072 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-center differences in outcomes
Number of subjects: 5972
Study 31443072 — intervention group
Group type: COMPARATOR
Intervention: Between-country differences in outcomes
Number of subjects: 5972
Study 28338977 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg d-cycloserine (DCS)
Number of subjects: 45
Study 28338977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SZ-PLC)
Number of subjects: 45
Study 26278911 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rEPO), high-dose, repetitive administration
Number of subjects: 120
Study 26278911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg CR
Number of subjects: 99
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg CR
Number of subjects: 99
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 20 mg CR
Number of subjects: 99
Study 24123224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (all dosages)
Number of subjects: 99
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg daily
Number of subjects: 99
Study 24123224 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 99
Study 21126245 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Synchrony
Number of subjects: 50
Study 21126245 — intervention group
Group type: COMPARATOR
Intervention: Non‐Interpersonal Synchrony
Number of subjects: 50
Study 18928483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Antegrade Warm Blood Cardioplegia (IAWBC) every 15 minutes
Number of subjects: 97
Study 18928483 — intervention group
Group type: COMPARATOR
Intervention: Modified Intermittent Antegrade Warm Blood Cardioplegia (M-IAWBC) with magnesium sulfate every 25 minutes
Number of subjects: 97
Study 16352396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala111Glu polymorphism of the glyoxalase I gene
Number of subjects: 450
Study 16352396 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 450
Study 12725766 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF patients
Number of subjects: 15
Study 12725766 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 15
Study 10690444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 4933
Study 10690444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme component interventions
Number of subjects: 4933
Study 10690444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programmes
Number of subjects: 4933
Study 1564212 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase with subcutaneous heparin
Number of subjects: 41600